

## **Response Biomedical Corp. Schedules Second Quarter 2012 Earnings Release and Announces Conference Call**

VANCOUVER, British Columbia – August 3, 2012

**Response Biomedical Corp.** (TSX: RBM, OTCBB: RPBIF) will release its second quarter financial results for the period ending June 30, 2012 after markets close on Tuesday, August 7, 2012.

Jeffrey L. Purvin, Chief Executive Officer, will host a conference call on Wednesday, August 8, 2012 at 3.00 p.m. PDT (6:00 p.m. EDT) to discuss the financial results for the second quarter. Participating in the call will be Richard Canote, Chief Financial Officer.

The conference call will be webcast live and is also available by dialing 1-877-643-7155 in North America or 1-914-495-8552 for all other locations. The conference ID number is 16482590 and participants are encouraged to initiate their calls at least 10 minutes in advance of the 3:00 p.m. PDT (6:00 p.m. EDT) start time to ensure a timely connection.

The webcast and earnings release will be accessible at: [Response Biomedical – Newsroom - Events Calendar: Corporate](#). A replay of the conference call will also be available there approximately two hours after the call and for 90 days thereafter.

### **About Response Biomedical Corp.**

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP<sup>®</sup> platform for clinical and environmental applications. RAMP<sup>®</sup> represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP<sup>®</sup> system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP<sup>®</sup> clinical tests are commercially available for the early detection of heart attack and congestive heart failure through our commercial partners and distributors.

In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.

Response Biomedical is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at [www.responsebio.com](http://www.responsebio.com).

### **About the RAMP® Reader and RAMP® 200 reader**

The RAMP® enabling platform is a portable scanning fluorescence quantitative analysis platform for near patient testing that enables rapid and robust quantitative results. The platform includes easy software upgrades, data management capabilities and unique interface options. The RAMP® Reader features a small footprint and attractive ease of use for moderate throughput settings. The RAMP® 200 reader has innovative design features, including the multi-port capability to run 18 tests per hour on one module and up to 36 tests per hour, using three modules. This allows tests to be run on multiple patients simultaneously or multiple assays to be run for one patient. More information on our proprietary RAMP® technology can be found at [www.responsebio.com](http://www.responsebio.com).

### **Forward-Looking Statements**

This press release may contain forward-looking statements. These statements relate to future events and are subject to assumptions about Response Biomedical Corporation. An example of a forward-looking statement in this press release includes a statement regarding future success of our efforts to drive overall market expansion for our RAMP® system. Forward-looking statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our amended annual report on Form 20-F, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities. We do not undertake to update any forward-looking statements.

### **Contacts**

#### **Response Biomedical Corp.:**

Patricia Massitti, 604-456-6010

VP, Administration & Corporate Communications

[pmassitti@responsebio.com](mailto:pmassitti@responsebio.com)